CL2015001914A1 - Composicion farmaceutica de liberacion demorada que comprende una forma de liberacion oral que tiene un nucleo que comprende un compuesto de biguanida y un recubrimiento enterico; y metodos para reducir eventos adversos de los compuestos, tratar trastornos metabolicos, reducir el inicio de la diabetes e inducir perdida de peso. - Google Patents

Composicion farmaceutica de liberacion demorada que comprende una forma de liberacion oral que tiene un nucleo que comprende un compuesto de biguanida y un recubrimiento enterico; y metodos para reducir eventos adversos de los compuestos, tratar trastornos metabolicos, reducir el inicio de la diabetes e inducir perdida de peso.

Info

Publication number
CL2015001914A1
CL2015001914A1 CL2015001914A CL2015001914A CL2015001914A1 CL 2015001914 A1 CL2015001914 A1 CL 2015001914A1 CL 2015001914 A CL2015001914 A CL 2015001914A CL 2015001914 A CL2015001914 A CL 2015001914A CL 2015001914 A1 CL2015001914 A1 CL 2015001914A1
Authority
CL
Chile
Prior art keywords
reduce
onset
diabetes
compounds
core
Prior art date
Application number
CL2015001914A
Other languages
English (en)
Inventor
Alain D Baron
Mark S Fineman
Terri Kim
Stephen Kwaku Dordunoo
Original Assignee
Elcelyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001914(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elcelyx Therapeutics Inc filed Critical Elcelyx Therapeutics Inc
Publication of CL2015001914A1 publication Critical patent/CL2015001914A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2015001914A 2013-01-05 2015-07-03 Composicion farmaceutica de liberacion demorada que comprende una forma de liberacion oral que tiene un nucleo que comprende un compuesto de biguanida y un recubrimiento enterico; y metodos para reducir eventos adversos de los compuestos, tratar trastornos metabolicos, reducir el inicio de la diabetes e inducir perdida de peso. CL2015001914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361749307P 2013-01-05 2013-01-05

Publications (1)

Publication Number Publication Date
CL2015001914A1 true CL2015001914A1 (es) 2015-09-04

Family

ID=50030486

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001914A CL2015001914A1 (es) 2013-01-05 2015-07-03 Composicion farmaceutica de liberacion demorada que comprende una forma de liberacion oral que tiene un nucleo que comprende un compuesto de biguanida y un recubrimiento enterico; y metodos para reducir eventos adversos de los compuestos, tratar trastornos metabolicos, reducir el inicio de la diabetes e inducir perdida de peso.

Country Status (18)

Country Link
US (2) US20140193498A1 (es)
JP (1) JP6333855B2 (es)
KR (1) KR102229492B1 (es)
CN (2) CN110051638B (es)
AR (1) AR094374A1 (es)
AU (1) AU2014203942B2 (es)
CA (1) CA2896864C (es)
CL (1) CL2015001914A1 (es)
CU (1) CU20150071A7 (es)
EA (1) EA039530B1 (es)
HK (1) HK1214966A1 (es)
IL (1) IL239722B (es)
MX (2) MX2020011594A (es)
NZ (1) NZ709525A (es)
PH (1) PH12015501520A1 (es)
SG (2) SG11201505240QA (es)
WO (1) WO2014107617A1 (es)
ZA (1) ZA201504858B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
EP3763419A1 (en) 2011-01-07 2021-01-13 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
EA033067B1 (ru) 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
ES2832773T3 (es) 2012-01-06 2021-06-11 Anji Pharma Us Llc Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos
SI3236943T1 (sl) * 2014-12-24 2023-06-30 Principia Biopharma Inc. Sestavki za dostavo zdravila v ileum-jejunum
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
FR3068601B1 (fr) * 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
MX2021014922A (es) * 2019-06-03 2022-03-11 Scherer Technologies Llc R P Capsulas de gel blando de liberacion retardada.
WO2023278300A1 (en) * 2021-06-28 2023-01-05 ImmunoMet Therapeutics, Inc. Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
EP1598054B1 (en) 1997-04-15 2011-03-16 Csir Non-therapeutic methods of suppressing appetite
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
PL362687A1 (en) * 2001-01-12 2004-11-02 Sun Pharmaceutical Industries Limited Spaced drug delivery system
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
EP1549296A4 (en) * 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co METFORMIN FORMULATIONS WITH DELAYED RELEASE
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
JP4654038B2 (ja) 2002-12-18 2011-03-16 ジボダン エス エー キメラアルファｑ−ガストデューシンｇタンパク質
DE10308504A1 (de) 2003-02-26 2004-09-09 Basf Ag Enzymatische Herstellung von (Meth)acrylsäureestern
CA2532332C (en) 2003-07-17 2007-10-02 Sante International, Inc. Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics
US8158372B2 (en) 2004-04-20 2012-04-17 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Agonists of a bitter taste receptor and uses thereof
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
EP1815015B1 (en) 2004-11-18 2012-05-23 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts Agonists of bitter taste receptors and uses thereof
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
RU2007144076A (ru) 2005-04-28 2009-06-10 Адзиномото Ко., Инк. (Jp) Новое производное лактама
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
US7939276B2 (en) 2005-06-22 2011-05-10 Senomyx, Inc. Assays which screen for compounds that modulate bitter taste of chlorogenic lactone compounds
US20080274180A1 (en) * 2005-08-30 2008-11-06 Nicholas Piramal India Limited Extended Release Pharmaceutical Composition of Metformin and a Process for Producing It
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (ja) 2006-01-11 2007-08-23 Canon Inc 情報処理装置及びその制御方法、プログラム、記憶媒体
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN101505771A (zh) 2006-08-17 2009-08-12 荷兰联合利华有限公司 含有甾体糖苷的hoodia植物萃取物的制造方法
MX2009001866A (es) 2006-08-24 2009-03-02 Unilever Nv Proceso para la preparacion de una composicion que comprende glucosidos esteroides.
WO2008030429A2 (en) 2006-09-05 2008-03-13 Senomyx, Inc. Novel haplotype of human t2r receptor ht2r50 and its use in assays for identifying human bitter taste modulators
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
WO2009053980A2 (en) 2007-10-24 2009-04-30 Arava Hoodia Growers A. C. S. Ltd. An improved appetite suppressant
EP2236149B1 (en) 2008-01-29 2014-06-18 Nakamori Pharmaceutical Co., Ltd. Medicinal composition for treating respiratory infectious diseases
US8546085B2 (en) 2008-06-13 2013-10-01 Givaudan Sa Methods of identifying modulators of the bitter taste receptor TAS2R44
EP2330103B1 (en) 2008-08-29 2015-10-07 Suntory Holdings Limited Novel epigallocatechin gallate tetramer, and vascular endothelial function improver comprising same
EP2329271B1 (en) 2008-08-29 2012-06-20 Givaudan SA Methods to identify modulators
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
CA2748729A1 (en) 2009-01-03 2010-07-08 Shizuoka Prefecture Public University Corporation Sulfated c-glycoside, method for isolating same and method for synthesizing same
US8709745B2 (en) 2009-07-28 2014-04-29 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Methods for isolating ligands of the human bitter taste receptor TAS2R49
AU2010310654B2 (en) 2009-10-21 2015-05-14 Wisconsin Alumni Research Foundation Method of preventing Type 1 diabetes
CA2779906A1 (en) 2009-12-04 2011-06-09 Colgate-Palmolive Company Oral compositions containing extracts of garcinia mangostana l. and related methods
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
CN101978956B (zh) * 2010-10-13 2012-03-28 北京京丰制药有限公司 盐酸二甲双胍肠溶片及其制备方法
EP3763419A1 (en) * 2011-01-07 2021-01-13 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
EA033067B1 (ru) * 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂

Also Published As

Publication number Publication date
SG10201705437SA (en) 2017-07-28
MX2015008625A (es) 2015-09-23
CA2896864A1 (en) 2014-07-10
JP6333855B2 (ja) 2018-05-30
US20200093750A1 (en) 2020-03-26
EA201591085A1 (ru) 2015-12-30
CA2896864C (en) 2021-04-20
ZA201504858B (en) 2018-12-19
MX2020011594A (es) 2022-01-13
CU20150071A7 (es) 2016-01-29
JP2016504384A (ja) 2016-02-12
EA039530B1 (ru) 2022-02-08
IL239722B (en) 2022-04-01
CN110051638A (zh) 2019-07-26
US20140193498A1 (en) 2014-07-10
AR094374A1 (es) 2015-07-29
AU2014203942A1 (en) 2015-07-16
HK1214966A1 (zh) 2016-08-12
EP2941245A1 (en) 2015-11-11
AU2014203942B2 (en) 2019-01-03
IL239722A0 (en) 2015-08-31
CN105101956A (zh) 2015-11-25
CN105101956B (zh) 2018-12-07
WO2014107617A1 (en) 2014-07-10
BR112015016111A2 (pt) 2020-01-28
KR102229492B1 (ko) 2021-03-17
KR20150103079A (ko) 2015-09-09
CN110051638B (zh) 2022-02-01
PH12015501520A1 (en) 2015-09-21
SG11201505240QA (en) 2015-08-28
NZ709525A (en) 2020-07-31

Similar Documents

Publication Publication Date Title
CL2015001914A1 (es) Composicion farmaceutica de liberacion demorada que comprende una forma de liberacion oral que tiene un nucleo que comprende un compuesto de biguanida y un recubrimiento enterico; y metodos para reducir eventos adversos de los compuestos, tratar trastornos metabolicos, reducir el inicio de la diabetes e inducir perdida de peso.
CL2013002612A1 (es) Compuestos derivados de c4-monometil triterpenoides; composicion farmaceutica que los comprende; y metodo para tratar o prevenir una enfermedad o un trastorno.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2016001079A1 (es) Nuevos compuestos para el combate de artrópodos.
DK3466949T3 (da) Tricyklisk forbindelse som anticancermidler
CL2016001077A1 (es) Nuevos compuestos para combatir artrópodos
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CO6990668A2 (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
CR20140259A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
BR112016011065A2 (pt) Composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
BR112012000968A2 (pt) composto, composição e método para inibir uma fosfatidil inositol-3 cinase.
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
CL2013003650A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo anti leucocidina luke y un portador farmaceuticamente aceptable.
CL2014001960A1 (es) Metodo para producir una composición que contiene galacto-oligosacáridos.
BR112014008196A2 (pt) processo para a preparação de um composto
CL2015000652A1 (es) Composiciones y métodos para la encapsulación doble de un compuesto volátil.
BR112014009950A2 (pt) composto dissubstituído, compostos e composição farmacêutica
BR112015003101A2 (pt) processo para a preparação de um composto.
CL2015000732A1 (es) Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
CO6970592A2 (es) Aproximación metabólica selectiva para aumentar biodisponibilidad oral de fenilefrina y otros bioactivos fenólicos
CO6852077A2 (es) Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales
BR112014014232A2 (pt) composto e método para a preparação de um composto
DK3052492T3 (da) Kondenserede 1,4-dihydrodioxin-derivater som hæmmere af varmechok-transskriptionsfaktor 1
CO7020909A2 (es) Compuesto tricíclicos, composiciones que los comprenden y uso de los mismos